Gastrointestinal stromal tumor medical therapy: Difference between revisions
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
**Diet and nutrition: Specific peri-operative diet and nutrition (multivitamin and mineral supplements) may given either through a Ryle's tube or a peripheral/central line f | **Diet and nutrition: Specific peri-operative diet and nutrition (multivitamin and mineral supplements) may given either through a Ryle's tube or a peripheral/central line f | ||
**Antibiotics cover: Patients with signs and symptoms of bowel perforation or infarction should be treated with intravenous antibiotic prophylaxis to prevent surgical wound infection and sepsis. | **Antibiotics cover: Patients with signs and symptoms of bowel perforation or infarction should be treated with intravenous antibiotic prophylaxis to prevent surgical wound infection and sepsis. | ||
**Pain and deep venous thrombosis prophylaxis: Appropriate pain control (NSAID or morphine) and prophylaxis for DVT (heparin) | **Pain and deep venous thrombosis prophylaxis: Appropriate pain control (NSAID or morphine) and prophylaxis for DVT (heparin) may be given as a precautionary therapy in patients complaining of pain or breathlessness. | ||
===Treatment Option Overview for GIST=== | ===Treatment Option Overview for GIST=== | ||
| Line 25: | Line 25: | ||
===Tyrosine Kinase Inhibitor Therapy=== | ===Tyrosine Kinase Inhibitor Therapy=== | ||
The tyrosine kinase inhibitor TKI [[imatinib mesylate]] is used as the first-line treatment for unresectable, metastatic, or recurrent GIST. Although complete responses are rare, a large majority of patients with metastatic or inoperable GIST have either a partial response or disease stabilization after starting [[imatinib]]. Median survival rates have gone from less than 2 years to more than 5 years since the advent of imatinib therapy. | |||
Therapy with neoadjuvant imatinib to reduce the tumor volume may be used for patients with very large primary GIST that cannot be removed without the risk of unacceptable morbidity. Additional therapy with adjuvant imatinib is being studied to determine whether imatinib reduces recurrence, which is common after resection of primary GIST. | Therapy with neoadjuvant imatinib to reduce the tumor volume may be used for patients with very large primary GIST that cannot be removed without the risk of unacceptable morbidity. Additional therapy with adjuvant imatinib is being studied to determine whether imatinib reduces recurrence, which is common after resection of primary GIST. | ||
Revision as of 16:33, 11 December 2017
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor medical therapy On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor medical therapy |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
The predominant therapy for gastrointestinal stromal tumor is surgical resection. Adjunctive chemotherapy/tyrosine Kinase Inhibitor therapy may be required.
Medical Therapy
- Laparoscopic surgical resection is the first-line treatment for primary and localized GIST. However, with advanced disease where surgery is not an option, patients are treated with chemotherapy. *Around 95 % patients with GIST stain positive for CD117 and therefore treated with agents acting against CD117.
- Medical therapy is also given as part of pre and post-operative care to reduce risk of morbidity associated with surgical resection of GIST.
- Pre and post operative fluid resuscitation and transfusion (ringer lactate). Urinary Foley catheter to monitor fluid output
- Diet and nutrition: Specific peri-operative diet and nutrition (multivitamin and mineral supplements) may given either through a Ryle's tube or a peripheral/central line f
- Antibiotics cover: Patients with signs and symptoms of bowel perforation or infarction should be treated with intravenous antibiotic prophylaxis to prevent surgical wound infection and sepsis.
- Pain and deep venous thrombosis prophylaxis: Appropriate pain control (NSAID or morphine) and prophylaxis for DVT (heparin) may be given as a precautionary therapy in patients complaining of pain or breathlessness.
Treatment Option Overview for GIST
- Surgical Therapy
- Chemotherapy
- Tyrosine Kinase Inhibitor Therapy
Chemotherapy
The advent of molecular genetics has drastically changed the outlook of patients with GIST. Prior to this, conventional chemotherapy were not effective in treating patients with GIST. Cells with MRP1 (multidrug resistance protein-1) and MDR-1 (multidrug resistance-1) gene produce P-glycoprotein which leads to increased cellular efflux pumps that prevented conventional chemotherapy agents to attain appropriate therapeutic levels.
Tyrosine Kinase Inhibitor Therapy
The tyrosine kinase inhibitor TKI imatinib mesylate is used as the first-line treatment for unresectable, metastatic, or recurrent GIST. Although complete responses are rare, a large majority of patients with metastatic or inoperable GIST have either a partial response or disease stabilization after starting imatinib. Median survival rates have gone from less than 2 years to more than 5 years since the advent of imatinib therapy.
Therapy with neoadjuvant imatinib to reduce the tumor volume may be used for patients with very large primary GIST that cannot be removed without the risk of unacceptable morbidity. Additional therapy with adjuvant imatinib is being studied to determine whether imatinib reduces recurrence, which is common after resection of primary GIST.
Because disease progression has been reported to follow the cessation of imatinib therapy, patients with unresectable or metastatic disease are often treated with a TKI indefinitely, as long as the disease does not progress and patient tolerance permits.
Drug side effects
The most common toxicities associated with imatinib therapy, all of which may improve with prolonged treatment, include the following:
- Fluid retention (especially periorbital edema or peripheral edema; occasionally pleural effusion or ascites)
- Diarrhea
- Nausea (may be diminished if taken with food)
- Fatigue
- Muscle cramps
- Abdominal pain
- Rash
- Mild (macrocytic) anemia
Treatment with sunitinib may be considered for patients with life-threatening side effects from imatinib that cannot be managed by maximum supportive care.[4] Common side effects associated with sunitinib therapy include the following:[22,36]
- Fatigue
- Nausea and vomiting
- Anemia
- Neutropenia
- Diarrhea
- Abdominal pain
- Mucositis
- Anorexia
- Skin or hair discoloration
- Hypothyroidism (thyroid function monitoring with TSH is generally recommended to detect subclinical hypothyroidism)